Early lung disease in cystic fibrosis

The Lancet Respiratory Medicine

Volumn 1, Issue 2, 2013, Pages 148-157

  Grasemann, Hartmut ^a   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; IVACAFTOR; MACROLIDE; MUCOLYTIC AGENT; SODIUM CHLORIDE; TOBRAMYCIN;

BRONCHIECTASIS; CFTR GENE; CHLORIDE TRANSPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; NEBULIZATION; NONHUMAN; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AIRWAY REMODELING; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; EARLY MEDICAL INTERVENTION; HUMANS; INFANT; INFLAMMATION; LUNG DISEASES; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM AGENTS; RESPIRATORY TRACT INFECTIONS;

EID: 84880046935     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70026-2     Document Type: Review

References (106)

1. Cystic Fibrosis Foundation patient registry: 2011 annual data report Cystic Fibrosis Foundation, (accessed March 4, 2013). http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf.
2. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991, 253:202-205.
3. Knowles MR, Olivier K, Noone P, Boucher RC Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis. Am J Respir Crit Care Med 1995, 151:65-69.
4. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493.
5. Chen JH, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010, 143:911-923.
6. Guilbault C, Saeed Z, Downey GP, Radzioch D Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007, 36:1-7.
7. Mall MA, Harkema JR, Trojanek JB, et al. Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med 2008, 177:730-742.
8. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
9. Day BJ, van Heeckeren AM, Min E, Velsor LW Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 2004, 72:2045-2051.
10. Green DM, Collaco JM, McDougal KE, Naughton KM, Blackman SM, Cutting GR Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J Pediatr 2012, 161:290-295.
11. Park JE, Yung R, Stefanowicz D, et al. Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection. Genes Immun 2011, 12:370-377.
12. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008, 118:1040-1049.
13. Dorfman R Modifier gene studies to identify new therapeutic targets in cystic fibrosis. Curr Pharm Des 2012, 18:674-682.
14. Sun L, Rommens JM, Corvol H, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 2012, 44:562-569.
15. Li W, Su D, Chiang T, et al. Do severity of early lung disease and meconium ileus in cystic fibrosis have common genetic contributors? 60th Annual Meeting of The American Society of Human Genetics; San Francisco, CA, USA; 6-10 Nov, 2012. 1322.
16. Bartlett JR, Friedman KJ, Ling SC Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009, 302:1076-1083. for the Gene Modifier Study Group.
17. Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976, 7:195-204.
18. Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012, 67:509-516.
19. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009, 180:146-152.
20. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009, 155:623-628.
21. Thia LP, Calder A, Owens C, et al. High resolution computed tomography (HRCT) in one year old CF newborn screened (NBS) infants: not a useful outcome measure. Pediatr Pulmonol 2012, 47:350.
22. de Jong PA, Lindblad A, Rubin L, et al. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006, 61:80-85.
23. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
24. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
25. Thursfield RM, Bush A, Alton EW, Davies JC Airway inflammation is present by 4 months in CF infants diagnosed on newborn screening. Pediatr Pulmonol 2012, 47:352.
26. Hoo AF, Thia LP, Nguyen TT, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012, 67:874-881.
27. Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007, 62:341-347.
28. Aurora P, Bush A, Gustafsson P, et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005, 171:249-256.
29. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011, 184:75-81.
30. Belessis Y, Dixon B, Hawkins G, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012, 185:862-873.
31. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28:321-328.
32. Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011, 306:163-171.
33. Wainwright CE, Grimwood K, Carlin JB, et al. Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatr Pulmonol 2008, 43:965-972.
34. Brody AS, Molina PL, Klein JS, Rothman BS, Ramagopal M, Swartz DR High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999, 29:731-735.
35. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007, 175:943-950.
36. Robinson TE, Goris ML, Zhu HJ, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest 2005, 128:2327-2335.
37. Nasr SZ, Gordon D, Sakmar E, et al. High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients. Pediatr Pulmonol 2006, 41:1129-1137.
38. Nasr SZ, Sakmar E, Christodoulou E, Eckhardt BP, Streetman DS, Strouse PJ The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol 2010, 45:440-449.
39. Eichinger M, Optazaite DE, Kopp-Schneider A, et al. Morphologic and functional scoring of cystic fibrosis lung disease using MRI. Eur J Radiol 2012, 81:1321-1329.
40. Puderbach M, Eichinger M, Gahr J, et al. Proton MRI appearance of cystic fibrosis: comparison to CT. Eur Radiol 2007, 17:716-724.
41. Gappa M, Ranganathan SC, Stocks J Lung function testing in infants with cystic fibrosis: lessons from the past and future directions. Pediatr Pulmonol 2001, 32:228-245.
42. Ranganathan SC, Bush A, Dezateux C, et al. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:1350-1357.
43. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008, 178:1238-1244.
44. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004, 23:93-97.
45. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012, 307:2269-2277.
46. Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007, 175:1304-1345.
47. Vilozni D, Bentur L, Efrati O, et al. Spirometry in early childhood in cystic fibrosis patients. Chest 2007, 131:356-361.
48. Kozlowska WJ, Bush A, Wade A, et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008, 178:42-49.
49. Kerby GS, Rosenfeld M, Ren CL, et al. Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting. Pediatr Pulmonol 2012, 47:597-605.
50. Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010, 65:379-383.
51. Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011, 37:806-812.
52. Ratjen FA, Sheridan H, Lee P-S, Song T, Stone A, Davies J Lung clearance index as an endpoint in a multicenter randomized control trial of Ivacaftor in subjects with cystic fibrosis who have mild lung disease. Am J Respir Crit Care Med 2012, 185:2819.
53. Subbarao P, Stanojevic S, Brown M, et al. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: A pilot study. Pediatr Pulmonol 2012, 47:350.
54. Boyle MP, De Boeck K A new era in cystic fibrosis therapeutics: Correcting the underlying CFTR defect. Lancet Respir Med 2013, published online Jan 30. 10.1016/S2213-2600(12)70057-7.
55. Stick S, Tiddens H, Aurora P, et al. Early intervention studies in infants and preschool children with cystic fibrosis: Are we ready?. Eur Respir J 2013, (in press).
56. Button BM, Heine RG, Catto-Smith AG, et al. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. Pediatr Pulmonol 2003, 35:208-213.
57. Rose MC, Voynow JA Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006, 86:245-278.
58. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990, 87:9188-9192.
59. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996, 51:119-125.
60. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992, 267:1947-1951.
61. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
62. McCoy K, Hamilton S, Johnson C Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996, 110:889-895.
63. Wilmott RW, Amin RS, Colin AA, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996, 153:1914-1917.
64. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001, 139:813-820.
65. Kearney CE, Wallis CE Deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2000, 2:CD001127.
66. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004, 169:719-725.
67. Konstan MW, Wagener JS, Pasta DJ, et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011, 46:545-553.
68. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001, 31:377-382.
69. McKenzie SG, Chowdhury S, Strandvik B, Hodson ME Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 2007, 42:928-937.
70. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997, 52:900-903.
71. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2008, 4:CD006458.
72. Ratjen F Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006, 354:291-293.
73. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
74. Subbarao P, Balkovec S, Solomon M, Ratjen F Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007, 42:471-476.
75. Dellon EP, Donaldson SH, Johnson R, Davis SD Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008, 43:1100-1106.
76. Rosenfeld M, Davis S, Brumback L, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol 2011, 46:666-671.
77. Al-Saleh S, Dell SD, Grasemann H, et al. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 2010, 157:1006-1011.
78. Henry RL, Mellis CM, Petrovic L Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12:158-161.
79. Ballmann M, Rabsch P, von der Hardt H Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998, 53:732-737.
80. Gibson RL, Burns JL, Ramsey BW Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
81. Ratjen F Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006, 12:428-432.
82. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998, 25:88-92.
83. Ratjen F, Doring G, Nikolaizik WH Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358:983-984.
84. Valerius NH, Koch C, Hoiby N Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
85. Munck A, Bonacorsi S, Mariani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001, 32:288-292.
86. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849.
87. Ratjen F, Munck A, Kho P, Angyalosi G Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
88. Ratjen F, Brockhaus F, Angyalosi G Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 2009, 8:361-369.
89. Amin R, Lam M, Dupuis A, Ratjen F The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr Pulmonol 2011, 46:554-558.
90. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165:847-856.
91. Ribeiro CM, Hurd H, Wu Y, et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One 2009, 4:e5806.
92. Ren CL Use of modulators of airways inflammation in patients with CF. Clin Rev Allergy Immunol 2002, 23:29-39.
93. Hillis GS, Pearson CV, Harding SA, et al. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study. Am Heart J 2004, 148:72-79.
94. Moskowitz SM, Foster JM, Emerson J, Burns JL Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004, 42:1915-1922.
95. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
96. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
97. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
98. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
99. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
100. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121:3554-3563.
101. Konstan MW, Byard PJ, Hoppel CL, Davis PB Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
102. Konstan MW, Schluchter MD, Xue W, Davis PB Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
103. Griese M, Latzin P, Kappler M, et al. α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007, 29:240-250.
104. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13:1423-1430.
105. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
106. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.